Nurix Therapeutics

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Nurix Therapeutics sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials 5 currently recruiting 2 completed early-phase tilt upper quartile by trial count

Nurix Therapeutics: 8 sponsored US clinical trials, 5 recruiting.

Nurix Therapeutics sponsors 8 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Small Lymphocytic Lymphoma (SLL), with 3 trials.

Upper-quartile sponsor footprint

Nurix Therapeutics sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

8 total, page 1 of 1

RECRUITING Phase 2

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

NCT07221500
RECRUITING Phase 1

Relative Bioavailability of NX-5948 Tablets vs Capsules and the Effect of Covariates on the PK of NX-5948 Tablets

NCT06717269
RECRUITING Phase 1

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

NCT05131022
RECRUITING Phase 1

A Study of NX-1607 in Adults With Advanced Malignancies

NCT05107674
RECRUITING Phase 1

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

NCT04830137
COMPLETED Phase 1

Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance Study of [14C] NX-5948

NCT06691828
COMPLETED Phase 1

A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult Subjects

NCT06593457
TERMINATED Phase 1

A Study of DeTIL-0255 in Adults With Advanced Malignancies

NCT05107739

Phase Distribution

PhaseTrial count
Phase 1 7
Phase 2 1

Therapeutic Areas

Small Lymphocytic Lymphoma (SLL) 3
Chronic Lymphocytic Leukemia (CLL) 3
Waldenstrom Macroglobulinemia (WM) 2
Marginal Zone Lymphoma (MZL) 2
Mantle Cell Lymphoma (MCL) 2
Follicular Lymphoma (FL) 2
Diffuse Large B Cell Lymphoma (DLBCL) 2
Primary Central Nervous System Lymphoma (PCNSL) 2
Malignant Pleural Mesothelioma (MPM) 1
Metastatic or Unresectable Melanoma 1

What is open in the Nurix Therapeutics pipeline

5 recruiting of 8 indexed (63% open); 2 completed (25%).

Phase mix: 0 late (III/IV) vs 8 early (I/II) (early-phase heavy).

Top condition: Small Lymphocytic Lymphoma (SLL) (3 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Nurix Therapeutics: open-pipeline peers nationwide

Peers matched on 8 registered trials and 63% open enrollment, not the therapeutic-area sidebar.

Nurix Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 681012141618 0%20%40%60%80% Total trials Recruiting share Nurix TherapeuticsAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Canadian Cancer Trials GroupCellSight TechnologiesCook Children's Health Care SystemPierre Fabre Medicament
Nurix Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Nurix Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 trials (± recruiting share)

Sponsors near 63% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Nurix Therapeutics page

8 registered trials is a research-attention snapshot, not an endorsement of Nurix Therapeutics or any single study.

  • 5 of Nurix Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Small Lymphocytic Lymphoma (SLL) is the condition Nurix Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Small Lymphocytic Lymphoma (SLL) trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Nurix Therapeutics pipeline card: 8 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.